EP3624810A4 - Immunothérapie anticancéreuse nano-activée - Google Patents
Immunothérapie anticancéreuse nano-activée Download PDFInfo
- Publication number
- EP3624810A4 EP3624810A4 EP18803111.6A EP18803111A EP3624810A4 EP 3624810 A4 EP3624810 A4 EP 3624810A4 EP 18803111 A EP18803111 A EP 18803111A EP 3624810 A4 EP3624810 A4 EP 3624810A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- immunotherapy
- nano
- cancer
- enabled
- enabled immunotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Ceramic Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762507996P | 2017-05-18 | 2017-05-18 | |
US201862614325P | 2018-01-05 | 2018-01-05 | |
PCT/US2018/033265 WO2018213631A1 (fr) | 2017-05-18 | 2018-05-17 | Immunothérapie anticancéreuse nano-activée |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3624810A1 EP3624810A1 (fr) | 2020-03-25 |
EP3624810A4 true EP3624810A4 (fr) | 2021-02-17 |
Family
ID=64274728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18803111.6A Pending EP3624810A4 (fr) | 2017-05-18 | 2018-05-17 | Immunothérapie anticancéreuse nano-activée |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3624810A4 (fr) |
AU (1) | AU2018269742B2 (fr) |
CA (1) | CA3063932A1 (fr) |
WO (1) | WO2018213631A1 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107073090A (zh) | 2014-04-30 | 2017-08-18 | 哈佛学院董事会 | 结合的疫苗装置和杀死癌细胞的方法 |
CN109072197A (zh) | 2016-02-06 | 2018-12-21 | 哈佛学院校长同事会 | 重塑造血巢以重建免疫 |
CN109789092A (zh) | 2016-07-13 | 2019-05-21 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
US11433143B2 (en) | 2017-05-18 | 2022-09-06 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
WO2020072366A1 (fr) * | 2018-10-01 | 2020-04-09 | The Regents Of The University Of California | Méthodes de traitement du cancer avec des activateurs de capteur d'arn double brin et une thérapie cellulaire adoptive |
WO2020243712A1 (fr) * | 2019-05-30 | 2020-12-03 | The Board Of Trustees Of The University Of Illinois | Activation de la procaspase-3 et immunothérapie destiné au traitement du cancer |
CN110585131A (zh) * | 2019-09-20 | 2019-12-20 | 宁夏医科大学 | 共载化疗药物的1-甲基色氨酸免疫前药胶束、制备方法及其应用 |
EP4034148A1 (fr) * | 2019-09-23 | 2022-08-03 | President and Fellows of Harvard College | Vaccin sans antigène à base de biomatériau et son utilisation |
EP4045054A4 (fr) * | 2019-10-14 | 2023-11-29 | The Regents of the University of California | Immunothérapie anticancéreuse nano-activée |
WO2021096542A1 (fr) | 2019-11-12 | 2021-05-20 | Nammi Therapeutics, Inc. | Compositions liposomales formulées et/ou co-formulées contenant des promédicaments antagonistes d'ido utiles dans le traitement du cancer et méthodes associées |
CN111333653A (zh) * | 2019-12-16 | 2020-06-26 | 山东大学 | 一种icd诱导剂-ido抑制剂缀合物及制备方法与应用 |
AU2020407871A1 (en) | 2019-12-20 | 2022-06-30 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof |
CN111012919B (zh) * | 2019-12-23 | 2021-06-01 | 山东大学 | 聚乙二醇化的icd诱导剂-ido抑制剂纳米缀合物及制备方法与应用 |
CN114945569A (zh) * | 2019-12-26 | 2022-08-26 | 延世大学校产学协力团 | 吡咯烷衍生物,以及包含其的用于预防或治疗β-淀粉样蛋白或Tau蛋白相关疾病的药物组合物 |
JP2023514324A (ja) | 2020-02-19 | 2023-04-05 | ナミ セラピューティクス, インコーポレイテッド | がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法 |
CN111330004B (zh) * | 2020-03-04 | 2023-02-10 | 中国人民解放军军事科学院军事医学研究院 | 二硫化钼纳米片层在制备树突状细胞功能促进剂中的应用 |
US20230201303A1 (en) * | 2020-05-04 | 2023-06-29 | Drugcendr Australia Pty Ltd. | Methods for treating pancreatic cancer and other solid tumors |
EP4180034A4 (fr) * | 2020-07-10 | 2024-01-03 | NADIANBIO Ltd. | Composition pharmaceutique pour la prévention ou le traitement du cancer, comprenant un composé à base de naphtoquinone et un inhibiteur de point de contrôle immunitaire en tant que principes actifs |
WO2022031605A1 (fr) * | 2020-08-07 | 2022-02-10 | The Regents Of The University Of California | Combinaison chimiothérapie-immunothérapie pour le cancer du pancréas au moyen d'effets immunogènes d'un nanosupport silicasome d'irinotécan et d'un anticorps anti-pd -1 |
WO2022055542A1 (fr) | 2020-09-10 | 2022-03-17 | Nammi Therapeutics, Inc. | Compositions liposomales formulées et/ou co-formulées contenant des promédicaments antagonistes de pd-1 utiles dans le traitement du cancer et méthodes associées |
EP4255460A1 (fr) * | 2020-12-01 | 2023-10-11 | The Trustees of Columbia University in the City of New York | Procédé de sensibilisation de cancers à une immunothérapie à l'aide d'agents immunomodulateurs |
CA3211133A1 (fr) | 2021-03-18 | 2022-09-22 | Nammi Therapeutics, Inc. | Compositions liposomales formulees et/ou co-formulees contenant des promedicaments antagonistes de a2ar utiles dans le traitement du cancer et procedes associes |
CN113332450B (zh) * | 2021-05-11 | 2023-08-04 | 铜仁学院 | 一种眼部给药递释系统氧化锌纳米粒的制备方法及其使用方法和应用 |
CN113353939B (zh) * | 2021-05-25 | 2023-09-08 | 中国科学院上海硅酸盐研究所 | 一种带隙可调、降解性可控的二维氢硅烯纳米材料及其制备方法和应用 |
CN114890385B (zh) * | 2021-07-01 | 2023-09-08 | 中国科学院上海硅酸盐研究所 | 一种高效抗氧化二维氢锗烯纳米片及其制备方法和应用 |
WO2023091168A1 (fr) | 2021-11-18 | 2023-05-25 | Nammi Therapeutics, Inc. | Compositions de nanosupports formulés et/ou co-formulés contenant des promédicaments induisant la mort cellulaire immunogène (icd) utiles dans le traitement du cancer et méthodes associés |
WO2023172300A1 (fr) * | 2022-03-10 | 2023-09-14 | The Regents Of The University Of California | Système de nanovecteur de médicament pour administrer une combinaison d'agonistes de tlr et/ou une lipoxine ainsi que des agents chimiothérapeutiques induisant la mort cellulaire immunogène pour une immunothérapie du cancer |
WO2023172347A1 (fr) | 2022-03-10 | 2023-09-14 | Nammi Therapeutics, Inc. | Compositions de nanovecteurs lipidiques formulés et/ou co-formulés contenant des promédicaments agonistes des récepteurs de type toll (tlr) utiles dans le traitement du cancer et méthodes associées |
WO2023183872A1 (fr) * | 2022-03-23 | 2023-09-28 | You First Services, Inc. | Nanoparticules contenant du delmopinol et un sel du delmopinol et leurs utilisations |
CN114748414B (zh) * | 2022-04-20 | 2024-05-31 | 中国医学科学院生物医学工程研究所 | 一种共负载化疗药和纳米粒的海藻酸钠水凝胶复合体系及其制备方法和应用 |
CN116327979B (zh) * | 2023-05-25 | 2023-08-01 | 西南石油大学 | 一种过渡金属基介孔纳米催化药物、制备方法及用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110159017A1 (en) * | 2008-04-11 | 2011-06-30 | Ludwig Institute For Cancer Research Ltd. | Trytophan catabolism in cancer treatment and diagnosis |
WO2017023667A1 (fr) * | 2015-07-31 | 2017-02-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Nanovecteur immunostimulateur |
WO2018140826A1 (fr) * | 2017-01-27 | 2018-08-02 | The Methodist Hospital | Plate-forme de structure noyau/enveloppe pour l'immunothérapie |
WO2019173391A1 (fr) * | 2018-03-06 | 2019-09-12 | Rita Elena Serda | Plate-forme à capacité élevée pour la mort de cellules cancéreuses immunogènes |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10828255B2 (en) * | 2013-03-05 | 2020-11-10 | The Regents Of The University Of California | Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents |
US11246877B2 (en) * | 2016-05-20 | 2022-02-15 | The University Of Chicago | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof |
-
2018
- 2018-05-17 EP EP18803111.6A patent/EP3624810A4/fr active Pending
- 2018-05-17 CA CA3063932A patent/CA3063932A1/fr active Pending
- 2018-05-17 WO PCT/US2018/033265 patent/WO2018213631A1/fr unknown
- 2018-05-17 AU AU2018269742A patent/AU2018269742B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110159017A1 (en) * | 2008-04-11 | 2011-06-30 | Ludwig Institute For Cancer Research Ltd. | Trytophan catabolism in cancer treatment and diagnosis |
WO2017023667A1 (fr) * | 2015-07-31 | 2017-02-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Nanovecteur immunostimulateur |
WO2018140826A1 (fr) * | 2017-01-27 | 2018-08-02 | The Methodist Hospital | Plate-forme de structure noyau/enveloppe pour l'immunothérapie |
WO2019173391A1 (fr) * | 2018-03-06 | 2019-09-12 | Rita Elena Serda | Plate-forme à capacité élevée pour la mort de cellules cancéreuses immunogènes |
Non-Patent Citations (3)
Title |
---|
ANU PURI ET AL: "Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic", PUBMED CENTRAL (PMC) AUTHOR MANUSCRIPT - HHS PUBLIC ACCESS, 14 June 2010 (2010-06-14), pages 1 - 48, XP055580417, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2885142/> [retrieved on 20190412] * |
JING-JING SUN ET AL: "Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier", ACTA PHARMACOLOGICA SINICA, vol. 38, no. 6, 8 May 2017 (2017-05-08), GB, pages 823 - 834, XP055580410, ISSN: 1671-4083, DOI: 10.1038/aps.2017.44 * |
See also references of WO2018213631A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2018269742B2 (en) | 2024-01-11 |
CA3063932A1 (fr) | 2018-11-12 |
WO2018213631A1 (fr) | 2018-11-22 |
EP3624810A1 (fr) | 2020-03-25 |
AU2018269742A1 (en) | 2019-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3624810A4 (fr) | Immunothérapie anticancéreuse nano-activée | |
IL261163B (en) | Methods related to crispr-cpf1, compositions and compositions for cancer immunotherapy | |
EP3364949A4 (fr) | Vaccins anticancéreux | |
EP3286361A4 (fr) | Néo-épitopes de cancer | |
EP3240801A4 (fr) | Immunothérapie anti-tumorale combinée | |
EP3280738A4 (fr) | Néo-épitopes du cancer | |
EP3226898A4 (fr) | Inhibiteur de bromodomaines comme adjuvant en immunothérapie anticancéreuse | |
EP3250695A4 (fr) | Cellules immunitaires universelles pour l'immunothérapie anticancéreuse | |
EP3160497A4 (fr) | Conjugués pour immunothérapie | |
EP3247408A4 (fr) | Compositions et procédés pour immunothérapie de cancer | |
EP3500262A4 (fr) | Compositions et méthode pour l'immunothérapie du cancer | |
EP3703711A4 (fr) | Compositions et méthodes pour le traitement du cancer avec une immunothérapie anti-ror1 | |
EP3474854A4 (fr) | Associations médicamenteuses pour le traitement du cancer | |
EP3413927A4 (fr) | Cancérothérapie | |
EP3597061A4 (fr) | Soutien-gorge | |
EP3390378A4 (fr) | Petites molécules contre le cancer | |
EP3202909A4 (fr) | Ribozyme à épissage spécifique du cancer, et son utilisation | |
EP3292140A4 (fr) | Immunothérapie du cancer | |
EP3265179A4 (fr) | Inhibiteurs de bêta-caténine dans l'immunothérapie du cancer | |
EP3347098A4 (fr) | Ciblage de l'activation de mda-5 pour l'immunothérapie du cancer | |
EP3733175A4 (fr) | Traitement du cancer | |
EP3310915A4 (fr) | Immunothérapie tumorale | |
EP3638247A4 (fr) | Compositions et méthodes pour améliorer le traitement par chimiothérapie du cancer | |
EP4045054A4 (fr) | Immunothérapie anticancéreuse nano-activée | |
EP3294863A4 (fr) | Dispositif de pharmacocinétique/pharmacodynamiquein vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191119 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031711500 Ipc: A61K0047500000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210118 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/7115 20060101ALI20210112BHEP Ipc: A61K 47/69 20170101ALI20210112BHEP Ipc: A61K 31/7125 20060101ALI20210112BHEP Ipc: A61K 47/50 20170101AFI20210112BHEP |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230524 |